Home > Research Institute > Available Trials > Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors
Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
Disease Types: Melanoma
Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
For more information: